Technology
Health
Biotechnology

Vascular Biogenics

$1.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.23%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VBLT and other stocks, options, ETFs, and crypto commission-free!

About

Vascular Biogenics Ltd. Ordinary Shares, also called Vascular Biogenics, is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. Read More It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Employees
37
Headquarters
Modi'in, Jerusalem
Founded
2000
Market Cap
57.73M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
163.89K
High Today
$1.65
Low Today
$1.55
Open Price
$1.63
Volume
74.00K
52 Week High
$3.10
52 Week Low
$0.60

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO

News

Seeking AlphaMar 19

VBL up 11% premarket on encouraging VB-111 data

VBL Therapeutics (NASDAQ:VBLT) is up 11% premarket on modestly higher volume on the heels of new data on anti-cancer gene therapy ofranergene obadenovec (VB-111). The results were presented at the SGO Annual Meeting on Women's Cancer in Honolulu.

81
Yahoo FinanceMar 14

Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline

Vascular Biogenics (VBLT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

49

Earnings

-$0.24
-$0.08
$0.08
$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.18 per share
Actual
Available Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.